You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
Initial data on the PARIS test, combining functional drug testing and DNA sequencing, showed concordance between its predictions and patients' treatment responses.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
The organoids could be grown to contain cellular features of the original tissue samples, enabling them to better mimic what occurs in the body than two-dimensional cultures.
In patients with Luminal B tumors the CDK4/6 inhibitor ribociclib along with hormonal therapy produced response rates similar to multi-agent chemotherapy.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.